NEJM Journal Watch: Oncology And Hematology RSS Feed
How Should We Advise Our Immunocompromised Patients After COVID-19 Vaccination£
Several recent cohort studies provide some guidance.
A Novel Method for Monitoring Anticoagulation with Warfarin
A modified test based on reductions in factor II and factor X was associated with a 56% reduction in total thromboembolic events.
Targeting Hairy Cell Leukemia
Vemurafenib plus rituximab provided durable remission in patients with relapsed or refractory disease.
Adjuvant Immunotherapy for High-Risk Bladder Cancer
Disease-free survival was improved with adjuvant nivolumab compared with placebo.
Adjuvant CDK4/6 Inhibitor in High-Risk Early-Stage Breast Cancer
In the PENELOPE-B trial, adding palbociclib to adjuvant endocrine therapy did not improve invasive-disease–free survival in patients with ER+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy.
Discontinuation of Complement-Inhibitor Therapy in Patients with Atypical Hemolytic Uremic Syndrome
In a prospective multicenter study, discontinuation was safe and feasible in patients without complement gene variant mutations.
Trastuzumab Deruxtecan Shows Promise in HER2-Positive Colorectal Cancer
The response rate was 45% and there were no new safety signals.
Next Generation Imaging: Impact on Postprostatectomy Salvage Therapy
The addition of 18F-fluciclovine-PET/CT to guide radiotherapy decisions improved event-free survival in patients without evidence of metastasis on conventional imaging.
A Third-Generation Bruton Tyrosine Kinase Inhibitor
Pirtobrutinib provided durable responses in patients with B-cell malignancies that were resistant to other BTKis.
Updated Recommendations for Colorectal Cancer Screening
The U.S. Preventive Services Task Force concludes, with moderate certainty, that screening confers moderate benefit to average-risk patients starting at age 45.
Feed Fetched by RSS Dog.